Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan

Purpose: Several studies have demonstrated significant interactions between immunosuppressants (e.g., cyclosporin A) and chemotherapeutic drugs that are BCRP substrates (e.g., irinotecan), resulting in increased bioavailability and reduced clearance of these agents. One possible mechanism underlying this observation is that the immunosuppressants modulate the pharmacokinetics of these drugs by inhibiting BCRP. Therefore, the aim of this study was to determine whether the immunosuppressants cyclosporin A, tacrolimus and sirolimus are inhibitors and/or substrates of BCRP. Methods: First, the effect of the immunosuppressants on BCRP efflux activity in BCRP-expressing HEK cells was measured by flow cytometry. Results: Cyclosporin A, tacrolimus and sirolimus significantly inhibited BCRP-mediated efflux of pheophorbide A, mitoxantrone and BODIPY-prazosin. The EC50 values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3±1.9 μM, 3.6±1.8 μM and 1.9±0.4 μM, respectively. Cyclosporin A, tacrolimus and sirolimus also effectively reversed resistance of HEK cells to topotecan and mitoxantrone conferred by BCRP. When direct efflux of cyclosporin A, tacrolimus and sirolimus was measured, these compounds were found not to be transported by BCRP. Consistent with this finding, BCRP did not confer resistance to the immunosuppressants in HEK cells. Conclusion: These results indicate that cyclosporin A, tacrolimus and sirolimus are effective inhibitors but not substrates of BCRP. These findings could explain the altered pharmacokinetics of BCRP substrate drugs when co-administered with the immunosuppressants and suggest that pharmacokinetic modulation by the immunosuppressants may improve the therapeutic outcome of these drugs.

[1]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[2]  S. Cole,et al.  Functional expression of the human breast cancer resistance protein in Pichia pastoris. , 2004, Biochemical and biophysical research communications.

[3]  L. Doyle,et al.  Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.

[4]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[5]  Ailan Guo,et al.  Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2) , 2004, BMC medicine.

[6]  F. Goldwasser,et al.  Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. , 2001, Anticancer Research.

[7]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F H Hausheer,et al.  Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  E. Wang,et al.  In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[10]  A. Fojo,et al.  Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. , 1995, British Journal of Cancer.

[11]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[12]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[13]  J. Petriz,et al.  Flow cytometry–based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[14]  P. Taylor.  Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry. , 2004, Therapeutic drug monitoring.

[15]  H. Rosing,et al.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Shiew-Mei Huang,et al.  FDA Evaluations Using In Vitro Metabolism to Predict and Interpret In Vivo Metabolic Drug‐Drug Interactions: Impact on Labeling , 1999, Journal of clinical pharmacology.

[17]  Jos H Beijnen,et al.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. , 2003, Cancer research.

[18]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[19]  G. Hall,et al.  Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  C. Hrycyna,et al.  Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A , 2005, Molecular Pharmacology.

[21]  G. Hall,et al.  Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. , 2003, Journal of Clinical Oncology.

[22]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[23]  A. Guo,et al.  Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[24]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[25]  J. Schellens,et al.  Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles , 2004, Cancer Research.

[26]  T. Ishikawa,et al.  Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. , 2001, Biochemical and biophysical research communications.

[27]  W. Greco,et al.  Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator , 2005, Clinical Cancer Research.

[28]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[29]  R. Wiesner,et al.  Hepatic allograft cyclosporine concentration is independent of the route of cyclosporine administration and correlates with the occurrence of early cellular rejection , 1992, Hepatology.

[30]  S. Cisternino,et al.  Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. , 2004, Cancer research.

[31]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  J. Unadkat,et al.  FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N , 2005, Drug Metabolism and Disposition.

[33]  S. Rabindran,et al.  Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. , 1998, Cancer research.

[34]  Y. Sugiyama,et al.  Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[35]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[36]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[37]  J. Schellens,et al.  Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Ratain,et al.  Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[40]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[41]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[42]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[43]  T. Litman,et al.  Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. , 2001, Biochemical and biophysical research communications.

[44]  Y. Nishiwaki,et al.  Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[45]  R. Schilsky,et al.  A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital , 2004, Clinical pharmacology and therapeutics.

[46]  D. Figgitt,et al.  Rosuvastatin , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[47]  T. Sakaeda,et al.  Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. , 2002, Biological & pharmaceutical bulletin.